Cabaletta Bio, Inc. (CABA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T cell therapies (CAR T and CAAR T) for autoimmune diseases. The lead product candidate, rese-cel (resecabtagene autoleucel), is in Phase 1/2 trials across multiple indications including myositis, systemic lupus erythematosus (SLE), systemic sclerosis, and pemphigus vulgaris. This report covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(43,515) | $(35,943) |
| Operating Expenses | $44,296 | $37,136 |
| Cash and Cash Equivalents (End of Period) | $116,635 | $131,830 |
| Accumulated Deficit | $(560,472) | $(385,044) |
| Net Cash Used in Operating Activities | $(42,561) | $(30,802) |
Note: The company has no revenue and operates at a loss. Margins are not applicable.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $7.6 million (21%) year-over-year, driven primarily by higher Research and Development (R&D) expenses.
- R&D Expense Growth: R&D expenses rose $8.3 million to $37.4 million. This was due to a $5.8 million increase in manufacturing costs (expanded cell processing and commercial readiness) and a $2.1 million increase in clinical trial costs (higher enrollment across multiple studies).
- Financing Activity: The company raised $22.6 million net from an "at-the-market" (ATM) offering and $6.9 million from warrant exercises during the quarter. This offset operating cash burn.
- Investing Activity: Net cash provided by investing activities was $51.0 million, primarily from the maturity of short-term investments ($50.96 million), compared to a small cash outflow in the prior year.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern. While current cash plus proceeds from a May 2026 financing ($141 million) are expected to fund operations into mid-2027, the company anticipates continuing significant losses and will require additional capital.
- Clinical Progress:
- Myositis: Initiated a registrational cohort in December 2025; BLA submission anticipated in 2027.
- SLE/LN: Registrational cohort designs announced; Phase 1/2 data expected in H1 2026.
- Manufacturing: Entered into agreements with Cellares for automated manufacturing (Cell Shuttle) and Lonza for global clinical development. Minaris agreement set to expire in August 2026.
- Key Risks:
- Capital Requirements: Need for substantial additional funding to complete development and commercialization.
- Regulatory Uncertainty: Reliance on single-arm trial designs with external controls (e.g., patient registries) for registrational trials, which may face FDA scrutiny.
- Manufacturing Dependence: Reliance on third-party manufacturers (Minaris, Lonza, Cellares) and potential supply chain disruptions.
- Intellectual Property: Dependence on licensed IP from IASO Biotherapeutics; termination would be materially adverse.
Investor Verification Checklist
- Verify the sufficiency of the $141 million raised in May 2026 to extend the cash runway to mid-2027 as projected.
- Monitor FDA feedback regarding the suitability of external control datasets for the registrational trials in myositis and SLE.
- Track the transition of manufacturing from Minaris (expiring August 2026) to Lonza and Cellares to ensure no clinical supply interruptions.
- Review upcoming data readouts for the no-preconditioning cohorts in SLE and Pemphigus Vulgaris expected in H2 2026.
- Assess the impact of the "BIOSECURE Act" and geopolitical tensions on supply chains involving China-based entities.